Encochleated Amphotericin B: Is the Oral Availability of Amphotericin B Finally Reached?

Aigner, Maria; Lass‐Flörl, Cornelia

doi:10.3390/jof6020066

Cited by 52 publications

(42 citation statements)

References 18 publications

(33 reference statements)

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Cochleatus, lat. = schraubenförmig, so wird AmB überlappend mit multiplen Phospholipidschichten schützend umgeben [30].…”

Section: Weiterentwicklungen Bekannter Stoffklassenunclassified

See 1 more Smart Citation

New Antimycotics in the Pipeline – For Ophthalmology Too?

Behrens–Baumann

2021

Klin Monbl Augenheilkd

View full text Add to dashboard Cite

Seven new antimycotics are presented that are at different points of development or approval. These substances are mainly first-in-class drugs. They are primarily developed for systemic administration. However, with the support of a pharmacist, the intravenous formulation may be used as eyedrops. In this short review, the activities of the substances against various fungal infections are described. After unsuccessful conventional therapy of fungal eye infections, one of these new substances might be suitable to cure the mycosis.

show abstract

“…Cochleatus, lat. = schraubenförmig, so wird AmB überlappend mit multiplen Phospholipidschichten schützend umgeben [30].…”

Section: Weiterentwicklungen Bekannter Stoffklassenunclassified

“…The spectrum of action is the same (cochleatus lat. = spiral; AmB is surrounded by multiple protective phospholipid layers) [30].…”

Section: Ar12 (Osu-03012); Arno Therapeutics Usamentioning

confidence: 99%

New Antimycotics in the Pipeline – For Ophthalmology Too?

Behrens–Baumann

2021

Klin Monbl Augenheilkd

View full text Add to dashboard Cite

show abstract

“…Cochleates form a multilayered structure composed of a negatively charged lipid (phosphatidylserine) and a divalent cation (calcium). This structure protects AmB from degradation within the gastrointestinal tract 51 . AmB is released to the fungus only when the cochleates interact with the target cells and subsequently destabilize in the setting of low intracellular calcium concentration.…”

Section: Agents Targeting the Cell Membrane Encochleated Amphotericin B (Mat2203)mentioning

confidence: 99%

Novel antifungal agents in clinical trials

2021

View full text Add to dashboard Cite

Invasive fungal diseases due to resistant yeasts and molds are an important and increasing public health threat, likely due to a growing population of immunosuppressed hosts, increases in antifungal resistance, and improvements in laboratory diagnostics. The significant morbidity and mortality associated with these pathogens bespeaks the urgent need for novel safe and effective therapeutics. This review highlights promising investigational antifungal agents in clinical phases of development: fosmanogepix, ibrexafungerp, rezafungin, encochleated amphotericin B, oteseconazole (VT-1161), VT-1598, PC945, and olorofim. We examine three first-in-class members of three novel antifungal classes, as well as new agents within existing antifungal classes with improved safety and tolerability profiles due to enhanced pharmacokinetic and pharmacodynamic properties.

show abstract

“…One of the main advantages of encochleated amphotericin B is its reduced toxicity and potential oral administration [ 10 ]. Nikkomycin inhibits chitin synthesis and has in vitro activity against fungal species that usually require long term therapy, such as those caused by Coccidioides immitis ; it has shown some activity in dog infections and synergistic activity in animals against Candida and Aspergillus infections.…”

mentioning

confidence: 99%